LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson’s Disease

Abstract

The G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson’s disease (PD). However, the molecular mechanisms of LRRK2 mutation contributing to the onset and progression of PD have not been fully illustrated. We generated HEK293 cells stably transfected with α-synuclein and investigated the effect of LRRK2 G2019S mutation on the degradation of α-synuclein. The lysosomal activity was assessed by the protein degradation of glyceraldehyde-3-phosphate dehydrogenase and ribonuclease A. It was found that α-synuclein was mainly degraded in lysosomes. LRRK2 G2019S inhibited the degradation of α-synuclein, and promoted its aggregation. LRRK2 G2019S also decreased the activities of lysosomal enzymes including cathepsin B and cathepsin L. Furthermore, the inhibitory effect of LRRK2 G2019S on lysosomal functions did not depend on its kinase activity. These findings indicated that the inhibitory effect of LRRK2 G2019S on α-synuclein degradation could underlie the pathogenesis of aberrant α-synuclein aggregation in PD with LRRK2 mutation.

Keywords

α-synuclein / leucine-rich repeat kinase 2 / Parkinson’s disease / lysosome

References

[1] OzansoyM, BasakAN. The central theme of Parkinson’s disease: alpha-synuclein. Mol Neurobiol, 2013, 47(2): 460-465

[2] LukKC, KehmV, CarrollJ, et al.. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 2012, 338(6109): 949-953

[3] KachergusJ, MataIF, HulihanM, et al.. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet, 2005, 76(4): 672-680

[4] LesageS, BriceA. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet, 2009, 18(R1): R48-59

[5] SepulvedaB, MesiasR, LiX, et al.. Short-and longterm effects of LRRK2 on axon and dendrite growth. PLoS One, 2013, 8(4): e61986

[6] WiderC, DicksonDW, WszolekZK. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis, 2010, 7(1-3): 175-179

[7] YaoC, El KhouryR, WangW, et al.. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. Neurobiol Dis, 2010, 40(1): 73-81

[8] LinX, ParisiadouL, GuXL, et al.. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alphasynuclein. Neuron, 2009, 64(6): 807-827

[9] NovelloS, ArcuriL, DoveroS, et al.. G2019S LRRK2 mutation facilitates alpha-synuclein neuropathology in aged mice. Neurobiol Dis, 2018, 120: 21-33

[10] McGlincheyRP, LeeJC. Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. Proc Natl Acad Sci USA, 2015, 112(30): 9322-9327

[11] WestAB, MooreDJ, BiskupS, et al.. Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA, 2005, 102(46): 16842-16847

[12] BlakeRA, BroomeMA, LiuX, et al.. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol, 2000, 20(23): 9018-9027

[13] TofarisGK. Lysosome-dependent pathways as a unifying theme in Parkinson’s disease. Mov Disord, 2012, 27(11): 1364-1369

[14] OsellameLD, DuchenMR. Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy, 2013, 9(10): 1633-1635

[15] KyratziE, PavlakiM, KontostavlakiD, et al.. Differential effects of Parkin and its mutants on protein aggregation, the ubiquitin-proteasome system, and neuronal cell death in human neuroblastoma cells. J Neurochem, 2007, 102(4): 1292-1303

[16] GongB, LeznikE. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect, 2007, 20(6): 365-370

[17] BennettMC, BishopJF, LengY, et al.. Degradation of alpha-synuclein by proteasome. J Biol Chem, 1999, 274(48): 33855-33858

[18] RideoutHJ, LarsenKE, SulzerD, et al.. Proteasomal inhibition leads to formation of ubiquitin/alphasynuclein-immunoreactive inclusions in PC12 cells. J Neurochem, 2001, 78(4): 899-908

[19] CuervoAM, StefanisL, FredenburgR, et al.. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science, 2004, 305(5688): 1292-1295

[20] ZimprichA, Muller-MyhsokB, FarrerM, et al.. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet, 2004, 74(1): 11-19

[21] HyunCH, YoonCY, LeeHJ, et al.. LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson’s Disease. Exp Neurobiol, 2013, 22(4): 249-257

[22] OrensteinSJ, KuoSH, TassetI, et al.. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci, 2013, 16(4): 394-406